Mirati Therapeutics Inc.’s cancer treatment Krazati (adagrasib) is having a tough time outside the U.S. The EMA’s Committee for Medicinal Products for Human Use (CHMP) came out with a negative opinion on an MAA for treating KRAS G12C-mutated advanced non-small-cell lung cancer (NSCLC). The ruling came with a flurry of positive CHMP opinions for companies, including Abbvie Inc., Beigene Ltd. and the Janssen Pharmaceutical Cos., plus a mixed result for Ipsen SA after a stumble earlier this week.
Research at Insilico Medicine Inc. has led to the development of CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disorders and inflammation.
Galectin-3 (LGALS3) and/or galectin-9 (LGALS9) inhibitors are reported in a Galecto Biotech AB patent as potentially useful for the treatment of cancer, autoimmune disease, fibrosis, cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among others.
Jeil Pharmaceutical Co. Ltd. has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, ulcerative colitis, rheumatoid arthritis, autoimmune disease, cardiovascular disorders and dermatological and inflammatory disorders and neurological disorders, among others.
Researchers from the Chinese University of Hong Kong have identified the Carnobacterium maltaromaticum bacterium as a potential oral probiotic prophylactic to increase vitamin D production and reinvigorate gut microbiota to prevent colorectal cancer (CRC) in women.
ArteraAI Inc. released data from a study it said validates the first-ever artificial intelligence (AI)-derived biomarker predicting the benefit of androgen deprivation therapy (ADT) for stripping prostate cancer of the testosterone it requires to grow.
Work at Shanghai Haihe Biopharma Co. Ltd. has led to the development of pyrimidine-2(1H)-one-fused bicyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors and thus reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG has prepared and tested heteroaromatic compounds described as GTPase KRAS G12C mutant inhibitors and reported to be useful for the treatment of cancer.
A Gossamer Bio Inc. patent describes oxime derivatives that act as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors and are thus reported to be useful for the treatment of cancer and viral infections.
RSS
